WASHINGTON (AP) — Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and ...

With the so-called wonder drugs coming under scrutiny, we look at the negative and positive side effects of taking them There has been meteoric demand for the weight loss drug Wegovy since it was ...

The popularity of semaglutide, the active ingredient in Ozempic and Wegovy, has skyrocketed in ... Zepbound (tirzepatide) and Saxenda (liraglutide) are two other options FDA-approved for weight ...

Sales of weight loss drug Wegovy more than doubled in the final three months of 2024, as manufacturer Novo Nordisk predicted growth will slow this year. The Danish pharmaceutical company has ...

Victoza sales declined 22% during the reported quarter. Obesity Care (Saxenda and Wegovy) sales were up 91% to DKK 21.4 billion. Wegovy sales continued to soar, recording DKK 19.9 billion in sales ...

The company's blockbuster semaglutide drugs, Wegovy for weight loss and Ozempic for diabetes, were key to its earnings beat. Combined, they brought in $24.9 billion for the year. That's compared ...

Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply improving this year, and brushed off fears of the company falling behind Eli Lilly & Co. Details about its next-generation weight loss drugs ...

Sales of weight loss drug Wegovy more than doubled in the final three months of 2024 but its manufacturer has predicted growth will slow this year. Novo Nordisk's rise to become one of Europe's ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs. Net profit for the fourth ...

Novo Nordisk reported soaring sales for weight loss drug Wegovy (James Manning/PA) Sales of weight loss drug Wegovy more than doubled in the final three months of 2024, as manufacturer Novo ...